What top creators are saying about Hims & Hers Health, Inc.(HIMS)— Page 2

Expected to benefit from lighter enforcement on compounded GLP-1s and telehealth services under new FDA leadership.

Investor is all-in at $26.72, anticipating a short squeeze due to 34% short interest and earnings on May 11, despite a lawsuit from Novo Nordisk.

Trading at an extremely cheap valuation despite strong growth and new GLP-1 partnerships.

The restoration of mail-order access for Mifepristone supports the growth of telehealth platforms specializing in reproductive health.

Host took a position based on personal product usage and following moves by respected community analysts.

Host exited position warning of a potential cool-down after a successful trade leg.

Highlighted as a retail 'hallucination yield' play driven by AI suggestions.

Viewed as a less attractive alternative to LFMD which owns its own supply chain.

Positive price action described as a 'sick candle' indicating strong upward momentum.

Highly bullish following a partnership with Eli Lilly; market reaction is considered muted relative to the deal's scale.

Described as having 'lost its juice' after a pump-and-dump reaction to a partnership announcement.

Contrarian long view at the $19 price level.

Stock rose 6% following a partnership with Eli Lilly for weight-loss drug access.

Transitioning to a high-margin tech-like business model by distributing Eli Lilly's GLP-1 drugs; strong cross-selling potential and AI-driven high-margin membership fees.

Facing pressure following Amazon's entry into the GLP-1 weight loss market.

Primary trade for the peptide and GLP-1 legalization trend, though facing competitive pressure from Amazon.

Discussed as a headline trade regarding reclassifications of weight-loss drugs.

Facing a fundamental shift and moat erosion after Amazon's One Medical launched a competing, lower-priced GLP-1 program.

While HIMS is seen as the industry standard for telehealth distribution, it faces long-term disruption risks from high-traffic influencers who may pivot from promoters to competitors by launching their own private-label platforms.

Amazon's entry into the GLP-1 and oral medication space threatens the company's margins and moat.

Stock fell 9% as Amazon enters the GLP-1 market, threatening the company's competitive moat.

Recent exit after 75% gain; belief that the market has priced in the RFK Jr. peptide narrative and attention has peaked.

Significant upside potential driven by the peptide narrative, vertical integration, and AI-driven diagnostics despite high volatility.

Mentioned in the context of 'look-maxing' and hair-loss prevention products.

Maintained as a core high-conviction growth holding despite recent market volatility.

Viewed as a high-momentum 'attention trade' tied to potential FDA regulatory shifts and GLP-1 trends, though faces risks from high P/E and lack of a proprietary moat.

Viewed as a high-conviction momentum trade driven by potential regulatory shifts for peptides and a self-reinforcing product flywheel.

Aligned with the longevity revolution and AI-driven healthcare trends, focusing on peptides and health optimization.

Significant growth catalyst from entry into GLP-1 and peptide manufacturing following a facility acquisition, coupled with a potential TAM expansion for TRT and a resilient direct-to-consumer business model.

Up 11% on peptide rumors; high short interest of 40% makes it a candidate for a short squeeze.

Primary way for traders to play the high-growth peptide and biotech regulation narrative.

Momentum trade driven by internet narratives and political mentions.

High-conviction short squeeze candidate following loosening of peptide restrictions.

The speaker remains invested despite high volatility, viewing peptides as a potential catalyst for long-term tech disruption.

Positioned as a primary play for the 'looksmaxxing' trend, though historically volatile and momentum-driven.

Regulatory de-risking of peptides and high short interest create a major revenue catalyst and short squeeze potential.

Positioned to lead the legitimate peptide market through regulatory clarity, in-house manufacturing, and a move toward partnerships with big pharma.

Surged on news of FDA moving toward regulatory clarity for peptide therapy.

Utilizes 'MedMatch' AI for personalized prescriptions and is undervalued as an underlying AI-driven platform rather than just a GLP-1 play.

High volatility and concerns regarding product side effects.

Up 8% but noted for high volatility and concerns regarding product side effects.

Considered 'dirt cheap' with a strong Rule of 40 score of 48 and defensive growth qualities decoupled from macro tensions.

Part of the expanded IA13 basket of high-growth AI-related companies.

Stock is down and speaker questions the long-term impact of product side effects.

Significant disconnect between fundamental performance and share price; 100,000 monthly weight loss subscriptions could add $210M in ARR not yet priced in.

The CFO's plan to sell 75% of his personal shareholdings and concerns over product concentration in hair loss treatments suggest a lack of executive confidence and high risk.

Shifting to a comprehensive healthcare disruptor using a 'loss-leader' strategy with lab screenings and proprietary EHR to capture long-term customers in weight loss and longevity.

Transitioning from a D2C provider to a healthcare disruptor by verticalizing infrastructure, including pharmacy fulfillment and diagnostics, while scaling GLP-1 accessibility.

Current price is a disconnect from strong fundamentals; company has a 95% recurring revenue model and is expanding into peptide manufacturing.

May benefit from compounded GLP-1 versions, but analysts are skeptical of long-term moat.